Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 2
1945 150
1946 262
1947 281
1948 512
1949 426
1950 516
1951 520
1952 682
1953 777
1954 627
1955 701
1956 760
1957 654
1958 568
1959 574
1960 599
1961 613
1962 696
1963 855
1964 984
1965 840
1966 894
1967 880
1968 907
1969 1068
1970 1088
1971 1143
1972 1179
1973 1189
1974 963
1975 1002
1976 1074
1977 1167
1978 1250
1979 1260
1980 1296
1981 1355
1982 1431
1983 1412
1984 1465
1985 1620
1986 1667
1987 1765
1988 1740
1989 1784
1990 1798
1991 1886
1992 1926
1993 1881
1994 1876
1995 1895
1996 1744
1997 2019
1998 1901
1999 1907
2000 1813
2001 1872
2002 1982
2003 2061
2004 2018
2005 2426
2006 2414
2007 2373
2008 2806
2009 3012
2010 3287
2011 3812
2012 3871
2013 3692
2014 4192
2015 3980
2016 4054
2017 4014
2018 3648
2019 3797
2020 4492
2021 4751
2022 4175
2023 3688
2024 1478

Text availability

Article attribute

Article type

Publication date

Search Results

136,160 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Trop-2 in solid tumors: future prospects.
Zaman S, Jadid H, Denson AC, Gray JE. Zaman S, et al. Onco Targets Ther. 2019 Mar 1;12:1781-1790. doi: 10.2147/OTT.S162447. eCollection 2019. Onco Targets Ther. 2019. PMID: 30881031 Free PMC article. Review.
Trop-2 is a transmembrane glycoprotein that is upregulated in all cancer types independent of baseline levels of Trop-2 expression. ...As a result, several Trop-2-targeted therapeutics have recently been developed for clinical use, such as anti-Trop-2 …
Trop-2 is a transmembrane glycoprotein that is upregulated in all cancer types independent of baseline levels of Trop-2 expres …
Trop-2 as a Therapeutic Target in Breast Cancer.
Sakach E, Sacks R, Kalinsky K. Sakach E, et al. Cancers (Basel). 2022 Nov 30;14(23):5936. doi: 10.3390/cancers14235936. Cancers (Basel). 2022. PMID: 36497418 Free PMC article. Review.
With sacituzumab govitecan, the first FDA-approved, Trop-2 inhibitor, providing a survival benefit in patients with both metastatic TNBC and hormone receptor positive breast cancer, additional Trop-2 directed therapies are under investigation. ...This review highlig …
With sacituzumab govitecan, the first FDA-approved, Trop-2 inhibitor, providing a survival benefit in patients with both metastatic T …
Targeting Trop-2 in cancer: Recent research progress and clinical application.
Qiu S, Zhang J, Wang Z, Lan H, Hou J, Zhang N, Wang X, Lu H. Qiu S, et al. Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188902. doi: 10.1016/j.bbcan.2023.188902. Epub 2023 Apr 29. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37121444 Free article. Review.
In this study, we reviewed the progress of Trop-2 research in solid tumors. We also sorted out the composition and rationale of Trop-2 related drugs and summarized the related clinical trials. ...Importantly, we found that Trop-2 targeted ADCs have great pote …
In this study, we reviewed the progress of Trop-2 research in solid tumors. We also sorted out the composition and rationale of Tr …
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M, Jacob S, Rugo HS, Hamilton E. Shastry M, et al. Breast. 2022 Dec;66:169-177. doi: 10.1016/j.breast.2022.10.007. Epub 2022 Oct 18. Breast. 2022. PMID: 36302269 Free PMC article. Clinical Trial.
TROP-2 expression is higher in HER2-negative breast tumors (HR+/HR-) and is associated with worse survival. Sacituzumab govitecan (SG) is a first-in-class TROP-2-directed ADC with an anti-TROP-2 antibody conjugated to SN-38, a topoisomerase inhibitor via a hy …
TROP-2 expression is higher in HER2-negative breast tumors (HR+/HR-) and is associated with worse survival. Sacituzumab govitecan (SG …
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.
Lombardi P, Filetti M, Falcone R, Altamura V, Paroni Sterbini F, Bria E, Fabi A, Giannarelli D, Scambia G, Daniele G. Lombardi P, et al. Cancers (Basel). 2023 Mar 13;15(6):1744. doi: 10.3390/cancers15061744. Cancers (Basel). 2023. PMID: 36980630 Free PMC article. Review.
Trop-2 overexpression was also described in several tumour types. ...In our work, we briefly summarize the various characteristics of cancer cells overexpressing Trop-2, the pre-clinical activities of specific inhibitors, and the role of anti-Trop-2 therapy i …
Trop-2 overexpression was also described in several tumour types. ...In our work, we briefly summarize the various characteristics of …
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
Belluomini L, Avancini A, Sposito M, Milella M, Rossi A, Pilotto S. Belluomini L, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1077-1087. doi: 10.1080/14712598.2023.2198087. Epub 2023 Apr 3. Expert Opin Biol Ther. 2023. PMID: 36995069 Review.
Several epithelial tumors harbor overexpression of the trophoblast cell-surface antigen 2 (TROP-2), which represents a predictor of poor prognosis and a promising target for anticancer therapy. ...EXPERT OPINION: Anti-TROP-2 ADCs represent an innovative upcoming wea …
Several epithelial tumors harbor overexpression of the trophoblast cell-surface antigen 2 (TROP-2), which represents a predictor of p …
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.
Goldenberg DM, Stein R, Sharkey RM. Goldenberg DM, et al. Oncotarget. 2018 Jun 22;9(48):28989-29006. doi: 10.18632/oncotarget.25615. eCollection 2018 Jun 22. Oncotarget. 2018. PMID: 29989029 Free PMC article. Review.
TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but subsequently shown to be increased in many solid cancers, with lower expression in certain normal tissues. It regulates cancer growth, invasion and spread by several signaling pathways, …
TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but subsequently shown to be increased in many sol …
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Goldenberg DM, et al. Oncotarget. 2015 Sep 8;6(26):22496-512. doi: 10.18632/oncotarget.4318. Oncotarget. 2015. PMID: 26101915 Free PMC article.
Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody. In vitro …
Trop-2 is a novel target for ADC therapy because of its high expression by many solid cancers. The rational development of IMMU-132 r …
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM. Cardillo TM, et al. Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8. Bioconjug Chem. 2015. PMID: 25915780
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) made from a humanized anti-Trop-2 monoclonal antibody (hRS7) conjugated with the active metabolite of irinotecan, SN-38. ...Current Phase I/II clinical trials ( ClinicalTrials.gov , NCT01631552) confirm a …
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) made from a humanized anti-Trop-2 monoclonal antibody (hRS7) con …
Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.
Trerotola M, Guerra E, Ali Z, Aloisi AL, Ceci M, Simeone P, Acciarito A, Zanna P, Vacca G, D'Amore A, Boujnah K, Garbo V, Moschella A, Lattanzio R, Alberti S. Trerotola M, et al. Neoplasia. 2021 Apr;23(4):415-428. doi: 10.1016/j.neo.2021.03.006. Epub 2021 Apr 8. Neoplasia. 2021. PMID: 33839455 Free PMC article.
Trop-2 is a transmembrane signal transducer that can induce cancer growth. ...No Trop-2 cleavage was detected in normal human tissues, whereas most tumors showed Trop-2 cleavage, including skin, ovary, colon, and breast cancers. ...
Trop-2 is a transmembrane signal transducer that can induce cancer growth. ...No Trop-2 cleavage was detected in normal human …
136,160 results
You have reached the last available page of results. Please see the User Guide for more information.